Application of Perilla frutescens in preparing medicine for treating cognitive dysfunction
By developing Perrin extract and preparing multiple dosage forms, the shortcomings of Alzheimer's disease and depression treatment were solved, and the spatial memory and learning ability of mice were significantly improved, indicating that it has potential efficacy in the treatment of Alzheimer's disease and clinical Application security.
Patent Information
- Application Number
- CN202311221860.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-09-21
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2043-09-21
AI Technical Summary
Currently, there is a lack of effective treatments for Alzheimer's disease and its combined depression, especially in Alzheimer's disease, and the medicinal value of Perrin has not been fully developed.
Through experimental screening, Perrin extract was developed for the preparation of drugs for the treatment of cognitive dysfunction. The immersion and reflux extraction methods were used to prepare a variety of dosage forms, such as tablets, granules, capsules, etc., for the improvement of mice Spatial memory and learning ability.
Perrin extract significantly improves spatial memory and learning ability in mice and increases neuronal growth, suggesting that it has potential efficacy in the treatment of Alzheimer's disease and depression, and is safe in clinical application.
Smart Images

Figure CN117100779B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a traditional Chinese medicine, in particular to application of Perilla frutescens in preparing medicines for treating cognitive dysfunction, and belongs to the technical field of medicines. Background Art
[0002] Alzheimer's disease (AD), also known as senile dementia, is a degenerative disease of the central nervous system and the most common type of dementia in the elderly. It is mainly manifested by neuropsychiatric symptoms such as progressive memory impairment, cognitive dysfunction, personality changes and language disorders, which seriously affect social, occupational and self-care functions. At present, the etiology and pathogenesis of AD have not been fully elucidated. The characteristic pathological changes are extracellular senile plaques formed by the deposition of β-amyloid protein and neurofibrillary tangles in nerve cells formed by hyperphosphorylation of tau protein, as well as neuronal loss accompanied by glial cell proliferation.
[0003] Perilla frutescens, which belongs to the spleen, stomach and lung meridians, has the functions of aromatic dehumidification, invigorating the spleen and appetizing, and relieving heat. It is used for dampness and turbidity blocking the middle part of the body, abdominal distension and nausea, sweet and greasy mouth, bad breath, excessive salivation, summer-dampness symptoms, and headache and chest tightness.
[0004] Currently, there are no reports on the use of Perlan to treat Alzheimer's disease and its combined depression. Summary of the invention
[0005] Purpose of the invention: Based on the existing uses of Perilla frutescens, the present invention screens its new clinical efficacy through experiments, develops its new uses, and studies the new efficacy of Perilla frutescens in the treatment of senile dementia and Alzheimer's disease.
[0006] Technical solution: In order to achieve the above purpose, the technical solution adopted by the present invention is:
[0007] Application of Perilla frutescens in preparing medicine for treating cognitive dysfunction.
[0008] Application of Perilla frutescens in preparing medicine for treating Alzheimer's disease.
[0009] Application of Perilla frutescens in the preparation of medicines for treating Alzheimer's disease combined with depression.
[0010] The perilla of the invention is prepared by the following method: weigh perilla, add 7 to 15 times of water, soak for 30 to 60 minutes, then reflux extract for 1 to 3 times, each time for 30 to 60 minutes, filter while hot; combine the filtrate; and reflux and concentrate the filtrate by vacuum condensation to obtain the perilla.
[0011] As a preferred embodiment, in the above-mentioned application, the perilla is prepared by the following method: weigh perilla, add 7 times the amount of water, soak for 30 minutes, then reflux extract for 30 minutes, and filter while hot; reflux extract the residue with 6 times the amount of water for 20 minutes, filter while hot, and combine the two filtrates; concentrate the filtrate to obtain the perilla extract.
[0012] The invention can prepare the perilla extract and a pharmaceutically acceptable carrier into lozenges, granules, tablets, pills, mixtures, powders, capsules or oral liquid preparations.
[0013] When preparing the lozenges, the perilla extract is added with a sweetener, a molding agent and / or a binder, mixed evenly, and then pressed into tablets to prepare the lozenges.
[0014] When the tablet is prepared, the carrier lactose or corn starch is added to the perilla extract, and the lubricant magnesium stearate is added when necessary, mixed evenly, and then pressed to form the tablet.
[0015] When the capsule is prepared, the fine powder of the perilla extract is added with carrier lactose or corn starch, mixed evenly, granulated, and then filled into capsules to prepare the capsule.
[0016] When preparing the granules, the fine powder of the perilla extract and the diluent lactose or corn starch are uniformly mixed, granulated, and dried to prepare the granules.
[0017] Beneficial effects: Compared with the prior art, the present invention has the following advantages:
[0018] (1) Based on the existing efficacy of Perilla frutescens extract, the present invention has conducted a large number of experimental screenings and water maze (MWM) and Y maze experimental studies, and found that Perilla frutescens extract can effectively improve the spatial memory and learning ability of mice, and can effectively improve the expression of cFOS in CA1 and CA3, and can also significantly increase the expression of cFOS in DG and improve the growth of neurons, indicating that Perilla frutescens extract has a good effect in improving Alzheimer's disease and depression. In addition, as a commonly used Chinese medicine in clinical practice, no adverse reactions were found during the experiment, and Perilla frutescens is safe for clinical application.
[0019] (2) The perilla extract provided by the present invention can be conveniently prepared into a variety of dosage forms with pharmaceutical carriers, and is convenient for clinical use. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 This is the effect of Perilla frutescens on the number of cFOS-positive cells in the hippocampal CA1, CA3 and dentate gyrus of scopolamine model mice (mean ± SEM, n = 6-8, *p < 0.05, **p < 0.01, ***p < 0.001).
[0021] Figure 2The changes in the number of Brdu and Ki67 positive cells in the dentate gyrus of the mouse hippocampus (mean ± SEM, n = 8, *p < 0.05, **p < 0.01, ***p < 0.001). DETAILED DESCRIPTION
[0022] The present invention can be better understood according to the following examples. However, it is easy for those skilled in the art to understand that the specific experimental conditions and results described in the examples are only used to illustrate the present invention, and should not and will not limit the present invention described in detail in the claims.
[0023] Example 1 Pharmacological screening experiment
[0024] 1. Experimental Methods
[0025] 1. Extraction of drugs
[0026] Perilla frutescens was provided by the Department of Traditional Chinese Medicine Preparations, Jiangsu Provincial Hospital of Traditional Chinese Medicine (Nanjing, China). Weigh 1000 g of Perilla frutescens, add 7 times the amount of water, soak for 30 minutes, then reflux extract for 30 minutes, and filter while hot. The residue was reflux extracted with 6 times the amount of water for 20 minutes, filtered while hot, and the two filtrates were combined. The filtrate was concentrated by vacuum condensation reflux (water temperature 55°C) to obtain Perilla frutescens extract.
[0027] 2. Animals
[0028] Male C57BL / 6J mice were purchased from Jiangsu Huachuang Xinnuo Pharmaceutical Technology Co., Ltd., China (Experimental Animal License No.: SCXK(SU)2020-0009). The average weight of mice was 18-22 g and they were 4 weeks old. All mice were adapted to a standard environment (12 / 12 light / dark, 23°C-25°C, humidity 40%±5%) 1 week before each experiment, with free access to water and food.
[0029] 3. Modeling method
[0030] Cognitive dysfunction model: The cognitive dysfunction model was established by chronic scopolamine (Scop) treatment. (Deng, G., Wu, C., Rong, X., Li, S., Ju, Z., Wang, Y., Ma, C., Ding, W., Guan, H., Cheng, X., Liu, W., Wang, C., 2019. Ameliorative effect of deoxyvasicine on scopolamine-induced cognitive dysfunction by restoration of cholinergic function in mice. Phytomedicine 63, 153007.) In this study, except for the blank control group, all other groups received chronic Scop modeling. Scop (CAS number: 51-34-3; MedChemExpress) was intraperitoneally injected at a dose of 1 mg / kg every day for 1 week to establish cognitive dysfunction in mice.
[0031] 4. Experimental Design
[0032] 40 mice were randomly divided into 5 groups: control group (Con), model group (Veh), low-dose group of Perilla frutescens extract (LC(L), 2.5g / kg), medium-dose group of Perilla frutescens extract (LC(M), 5.0g / kg), and high-dose group of Perilla frutescens extract (LC(H), 7.5g / kg). Except for the blank group, the other groups were subjected to chronic Scop modeling. Before the 7-day Scop modeling, the mice were gavaged with Perilla frutescens extract every day for two weeks. In order to ensure the consistency of experimental conditions, all other Scop groups and LC groups that were not administrated were replaced with 0.9% normal saline.
[0033] 5. Behavioral Testing
[0034] Water maze (MWM): MWM is used to assess spatial memory and learning ability (Nunez, 2008). The water maze consists of a circular pool (1.3m in diameter) and a circular platform (6cm in diameter). The circular pool is randomly divided into four equal parts (north, south, east, and west), and the platform is placed in a fixed quadrant. The circular pool is filled with water (water temperature: 22-24℃), and its liquid level is about 1 cm below the platform. The experiment was conducted in two parts, including training and testing. Training: The mice were gently placed in the quadrant farthest from the platform (facing the pool wall), and the time required for them to freely explore and successfully land on the platform was observed. If they successfully located and landed on the platform, they were allowed to stay on the platform for 15s; if they did not find the platform within 90s, a guide rod was used to assist them in finding and landing on the platform and staying for 15s. This training was conducted at a unified time, once a day, for 5 consecutive days. Testing: The test was divided into two conditions: with a platform and without a platform. Platform condition: During the training process, the mouse is gently placed in the water from the same position, and the time from being placed in the water to the platform is measured, which is called the latency period. No platform condition: After removing the platform, the mouse is placed in the water from the same position, and the number of times the mouse crosses the platform position within 90 seconds is measured. Use any maze software to record the latency period of the mouse reaching the platform and the number of times the mouse crosses the platform during the test.
[0035] Y-maze: Spontaneous alternation in the Y-maze was used to assess spatial working memory ability. In brief, the three arms of the Y-maze were labeled A, B, and C. The mouse was placed in the center of arm A and allowed to move freely for 10 minutes, and the order in which the mouse entered each arm during this process was recorded. When the mouse entered different arms of the maze, it was considered to have spontaneously alternating, and the total number of spontaneous alternations was calculated. The calculation formula for the percentage of spontaneous alternation is as follows: Spontaneous alternation (%) = number of spontaneous alternations / (total number of entries into the arm-2).
[0036] 6. Data Analysis
[0037] All data are presented as mean ± SEM. Two-tailed student t-test was used to analyze two different groups of samples. For comparisons of more than two groups, one-way analysis of variance or two-way analysis of variance followed by Tukey's post hoc test was applied. All data were analyzed using SPSS 19.0 software (SPSS, USA). Unless otherwise stated, statistical significance was accepted at least at the 5% level.
[0038] 2. Experimental Results
[0039] 1. The water maze has platforms
[0040] In the water maze experiment with platforms, it can be seen from Table 1 that compared with the blank group mice, the latency of the model group mice to enter the platform was longer and significantly higher (P<0.001), indicating that Scop modeling reduced the spatial memory and learning ability of mice; compared with the model group, the latency of the mice in the low-dose, medium-dose and high-dose orchid groups to enter the platform was significantly reduced (low-dose orchid group P<0.01, medium-dose orchid group P<0.001, high-dose orchid group P<0.05), and the medium-dose orchid group had a greater reduction, indicating that Perilla extract can effectively improve the reduction in spatial memory and learning ability of mice, and the medium-dose orchid is more effective.
[0041] Table 1 Effects of different doses of orchid on the latency of entering the platform in the water maze test of mice ( n=8)
[0042] Group n Dosage Incubation period (sec) Blank Group 8 0 21.30±14.69 Model Group 8 0 <![CDATA[70.86±22.35 *** ]]> Perilla Extract Group 1 8 2.5g / kg <![CDATA[24.13±20.69 ### ]]> Perilla Extract Group 2 8 5.0g / kg <![CDATA[32.08±20.25 ## ]]> Perilla Extract Group 3 8 75g / kg <![CDATA[3902±3606 # ]]>
[0043] (Note: Compared with the blank control group, ***P<0.001; compared with the model group, #P<0.05, ##P<0.01, ###P<0.001)
[0044] 2. Water maze without platform
[0045] In the water maze experiment without a platform, it can be seen from Table 2 that compared with the blank group mice, the number of times the model group mice crossed the platform position was significantly reduced (P<0.01), indicating that Scop modeling reduced the spatial memory and learning ability of mice; compared with the model group, the number of times the mice in the low-dose orchid group, the medium-dose orchid group, and the high-dose orchid group crossed the platform position was significantly increased (low-dose orchid group P<0.01, medium-dose orchid group P<0.01, high-dose orchid group P<0.01), and the number of crossings by mice in the low-dose orchid group was more, indicating that Perilla extract can effectively improve the reduction in spatial memory and learning ability of mice.
[0046] Table 2 Effects of different doses of orchid on the number of times mice entered the platform in the water maze test without platform n=8)
[0047] Group n Dosage Crossing times (time) Blank Group 8 0 2.75±0.89 Model Group 8 0 <![CDATA[1.15±0.80 ** ]]> Perilla Extract Group 1 8 2.5g / kg <![CDATA[3.50±1.41 ## ]]> Perilla Extract Group 2 8 5.0g / kg <![CDATA[3.13±1.64 ## ]]> Perilla Extract Group 3 8 7.5g / kg <![CDATA[3.38±1.40 ## ]]>
[0048] (Note: Compared with the blank control group, **P<0.01; compared with the model group, ##P<0.01)
[0049] 3. Y-maze
[0050] In the Y-maze experiment, as shown in Table 3, compared with the mice in the blank group, the percentage of sequential cycles in the three quadrants of the Y-maze in the model group was significantly reduced (P<0.01), indicating that Scop modeling weakened the spatial working memory ability of mice; compared with the model group, the percentage of sequential cycles in the three quadrants of the Y-maze in the low-dose, medium-dose and high-dose orchid groups was significantly increased (low-dose orchid group P<0.001, medium-dose orchid group P<0.01, high-dose orchid group P<0.01), and the percentage of low-dose orchid was even higher, indicating that Perilla extract can significantly improve the lack of spatial working memory ability in mice.
[0051] Table 3 Effects of different doses of orchid on the percentage of sequential cycles of the three quadrants of the Y maze in mice ( n=8)
[0052] Group n Dosage percentage(%) Blank Group 8 0 64.29±4.69 Model Group 8 0 <![CDATA[49.58±7.10 ** ]]> Perilla Extract Group 1 8 2.5g / kg <![CDATA[67.28±4.61 ### ]]> Perilla Extract Group 2 8 5.0g / kg <![CDATA[66.31±6.21 ## ]]> Perilla Extract Group 3 8 7.5g / kg <![CDATA[59.84±5.12 ## ]]>
[0053] (Note: Compared with the blank control group, **P<0.01; compared with the model group, ##P<0.01, ###P<0.001)
[0054] Based on the above three experimental tests, low doses of Perilla frutescens extract are better in improving the spatial memory and learning ability of mice.
[0055] Example 2
[0056] 1. Experimental Methods
[0057] 1. Extraction of drugs
[0058] Perilla frutescens was provided by the Department of Traditional Chinese Medicine Preparations, Jiangsu Provincial Hospital of Traditional Chinese Medicine (Nanjing, China). Weigh 1000 g of Perilla frutescens, add 7 times the amount of water, soak for 30 minutes, then reflux extract for 30 minutes, and filter while hot. The residue was reflux extracted with 6 times the amount of water for 20 minutes, filtered while hot, and the two filtrates were combined. The filtrate was concentrated by vacuum condensation reflux (water temperature 55°C) to obtain Perilla frutescens extract.
[0059] 2. Animals
[0060] Male C57BL / 6J mice were purchased from Jiangsu Huachuang Xinnuo Pharmaceutical Technology Co., Ltd., China (Experimental Animal License No.: SCXK(SU)2020-0009). The average weight of mice was 18-22 g and they were 4 weeks old. All mice were adapted to a standard environment (12 / 12 light / dark, 23°C-25°C, humidity 40%±5%) 1 week before each experiment, with free access to water and food.
[0061] 3. Modeling method
[0062] Same as Example 1.
[0063] 4. Experimental Design
[0064] 40 mice were randomly divided into 4 groups: blank group (Con), model group (Veh), Perilla extract group (LC), Yangshen group and donepezil group (Don, 5.0 mg / kg; CAS number: HY-14566; MedChemExpress). Except for the control group, all other groups received chronic Scop modeling. Before the 7-day Scop modeling, the LC group and the Don group were gavaged daily for 2 weeks. In order to maintain the consistency of experimental conditions, all other unadministered Scop, LC and Don groups were given the same stimulation with 0.9% saline.
[0065] 5. Behavioral Testing
[0066] Water maze (MWM): Same as Example 1.
[0067] Y maze: Same as Example 1.
[0068] 6. Immunofluorescence
[0069] Immunofluorescence was used to detect the expression of cFOS, an indicator related to neuronal learning and memory activity, and Ki67, Brdu, and doublecortin (DCX), indicators related to neurogenesis, in the hippocampus. The mouse brain was perfused with 4% paraformaldehyde and fixed overnight. 20-micron frozen microsections were taken for immunofluorescence experiments for every six slices. Tissue slices were taken and 0.4% triton was added to react at room temperature for 20 minutes. Then the tissue slices were rinsed with 0.01M PBS for 5 minutes / 3 times, and then microwaved with 0.01mmol / l citrate for thermal repair, high temperature for 5 minutes, low temperature for 20 minutes, and naturally cooled for about 1 hour. The tissue slices were washed for 5 minutes / 3 times, 2MHCL was added, 37℃ for 30 minutes, and then 0.01M tris-HCL was added at room temperature for 10 minutes. The sections were blocked with bovine serum albumin (BSA) / 0.3% TritonX-100 / PBS for 1 hour, and rabbit anti-FOS (1:500, Abcam, ab214672), rabbit anti-Ki67 (1:500, Abcam, ab16667), rabbit anti-Brdu (1:500, Abcam, ab152095), and mouse anti-doublecortin (1:500, Abcam, ab135349) were used overnight at 4°C. Secondary antibodies used were anti-rabbit IgG (1:500, Abcam, ab150080, Alexa Fluor 594), anti-mouse IgG (1:500, Abcam, ab150113, Alexa 488) and incubated at room temperature for 1 hour without cross-reaction. Rinse three times with 0.01M PBS between each step. Confocal quantification was performed using DAPI antifade mounting, laser confocal scanning imaging, and Image J software.
[0070] 7. Data Analysis
[0071] All data are presented as mean ± SEM. Two-tailed student t-test was used to analyze two different groups of samples. For comparisons of more than two groups, one-way analysis of variance or two-way analysis of variance followed by Tukey's post hoc test was applied. All data were analyzed using SPSS 19.0 software (SPSS, USA). Unless otherwise stated, statistical significance was accepted at least at the 5% level.
[0072] 2. Experimental Results
[0073] 1. The water maze has platforms
[0074] In the water maze experiment with platforms, it can be seen from Table 4 that compared with the blank control group mice, the latency of the model group mice to enter the platform was longer and significantly significant (P<0.001), indicating that Scop modeling reduced the spatial memory and learning ability of mice; compared with the model group, the latency of the mice in the Perilla extract group and the Yangshen group to enter the platform was significantly reduced (Perilla extract group P<0.01, Yangshen group P<0.01), and the latency of the Yangshen group was even lower, indicating that Perilla extract and donepezil have similar effects on improving the spatial memory and learning ability of mice.
[0075] Table 4 Effect of orchid grass on the latency of entering the platform in the water maze test of mice ( n=10)
[0076] Group n Dosage Incubation period (sec) Blank Group 10 0 21.47±13.85 Model Group 10 0 <![CDATA[66.49±25.19 *** ]]> Perilla extract group 10 2.5g / kg <![CDATA[31.18±19.30 ## ]]> Yangshen Group 10 5.0mg / kg <![CDATA[28.53±22.68 ## ]]>
[0077] (Note: Compared with the blank control group, ***P<0.001; compared with the model group, ## P<0.01)
[0078] 2. Water maze without platform
[0079] In the water maze experiment without a platform, it can be seen from Table 5 that compared with the mice in the blank group, the number of times the mice in the model group crossed the platform position was significantly reduced (P<0.001), indicating that Scop modeling reduced the spatial memory and learning ability of mice; compared with the model group, the number of times the mice in the Perilla extract group and the Yangshen group crossed the platform position was significantly increased (Perilla extract group P<0.001, Yangshen group P<0.001), and the number of times the mice in the Perilla extract group crossed the platform was more, indicating that Perilla extract and donepezil can effectively improve the spatial memory and learning ability of mice.
[0080] Table 5 Effect of bluegrass on the number of times mice enter the platform in the water maze test without platform n=10)
[0081] Group n Dosage Number of crossings Blank Group 10 0 3.0±0.67 Model Group 10 0 <![CDATA[1.22±0.76 *** ]]> Perilla extract group 10 2.5g / kg <![CDATA[3.60±1.35 ### ]]> Yangshen Group 10 5.0mg / kg <![CDATA[3.10±0.99 ### ]]>
[0082] (Note: Compared with the blank control group, ***P<0.001; compared with the model group, ### P<0.001)
[0083] 3. Y-maze
[0084] In the Y-maze experiment, as shown in Table VI, compared with the mice in the blank group, the percentage of sequential cycles in the three quadrants of the Y-maze in the model group was significantly reduced (P<0.001), indicating that Scop modeling weakened the spatial working memory ability of mice; compared with the model group, the percentage of sequential cycles in the three quadrants of the Y-maze in the Perilla extract group and the Yangshen group was significantly increased (Perilla extract group P<0.001, Yangshen group P<0.01), and the percentage in the Perilla extract group was even higher, indicating that Perilla extract and donepezil can significantly improve the spatial working memory ability of mice.
[0085] Table 6 The percentage effect of bluegrass on the sequential cycle of the three quadrants of the Y maze of mice ( n=10)
[0086] Group n Dosage percentage(%) Blank Group 10 0 65.56±4.19 Model Group 10 0 <![CDATA[50.83±7.07 *** ]]> Perilla extract group 10 2.5g / kg <![CDATA[67.63±5.56 ### ]]> Yangshen Group 10 5.0mg / kg <![CDATA[63.82±7.77 ## ]]>
[0087] (Note: Compared with the blank control group, ***P<0.001; compared with the model group, ## P<0.01, ### P<0.001)
[0088] 4. Effects of Perilla on learning and memory activities of hippocampal neurons
[0089] The immediate early gene cFOS is upregulated due to learning and memory activities of neurons and can be used as a marker of neuronal activity. Therefore, the present invention detected the expression of cFOS in different regions of the hippocampus (including CA1, CA3 and dentate gyrus (DG)) of mice induced by scopolamine after receiving perlan (LC) treatment. The experiment found that the expression of cFOS in the CA1 and CA3 brain regions of the hippocampus in the model group was reduced, but no changes were found in the DG. Perlan can not only significantly improve the expression of cFOS in CA1 and CA3, but also significantly increase the expression of cFOS in DG ( Figure 1 However, the cFOS expression in the hippocampus of the Yangshen group (Don) did not improve ( Figure 1 ). This indicates that Perilla has the effect of enhancing the learning and memory activities of hippocampal neurons.
[0090] 5. Effect of Perilla on Hippocampal Neurogrowth
[0091] AD is characterized by neuronal loss, and enhancing neural growth can improve the cognitive impairment of AD. Neural growth mainly goes through three stages: proliferation, migration, and differentiation of neural stem cells. Therefore, the effect of Perilla on hippocampal neurogenesis was explained by immunofluorescence labeling of Ki67, BrdU, and DCX, which are related indicators of cell proliferation in the hippocampus. The results showed that the expression of Ki67 in DG of the model group was significantly reduced, but it had no effect on the expression of BrdU. After Perilla treatment, the expression of BrdU and Ki67 increased significantly ( Figure 2 ). This suggests that Perilla can enhance nerve growth and has the effect of treating AD.
[0092] Based on the above experimental tests, Perilla extract is better than nepezil in improving the spatial memory and learning ability of mice, and can significantly improve the expression of cFOS in CA1 and CA3 and significantly increase the expression of cFOS in DG. It can also increase the growth of neurons, suggesting that it can be developed for the treatment of diseases such as Alzheimer's disease.
[0093] The above implementation modes are only for illustrating the technical concept and features of the present invention, and their purpose is to enable people familiar with this technology to understand the content of the present invention and implement it, and they cannot be used to limit the protection scope of the present invention. Any equivalent changes or modifications made according to the spirit of the present invention should be included in the protection scope of the present invention.
Claims
1. Use of Perilla frutescens extract as the sole active ingredient in the preparation of drugs for treating Alzheimer's disease; The perilla extract is prepared by the following method: weigh perilla, add 7 to 15 times the amount of water, soak for 30 to 60 minutes, then reflux extract 1 to 3 times, each time for 30 to 60 minutes, filter while hot; combine the filtrate; and condense the filtrate by vacuum condensation reflux to obtain the extract.
2. The use according to claim 1, characterized in that: The perilla extract is prepared by the following method: weigh perilla, add 7 times the amount of water, soak for 30 minutes, then reflux extract for 30 minutes, filter while hot; reflux extract the residue with 6 times the amount of water for 20 minutes, filter while hot, and combine the two filtrates; The filtrate was concentrated to obtain the perilla extract.
3. The use according to claim 1 or 2, characterized in that: The perilla extract and a pharmaceutically acceptable carrier are prepared into granules, tablets, pills, mixtures, powders or capsules.
